Table 2.
Targeted drugs developed by Chinese pharmaceutical companies that were approved by the NMPA in 2019
| No. | Drug name | Active ingredient | Approval date | Target/Activity | CFDA-approved use on approval date* | Drug class | Company |
|---|---|---|---|---|---|---|---|
| 1 | Bite | Carrimycin | 6/24/19 | β-lactamase | Bacterial infection of the upper respiratory tract, resistant Mycobacterium tuberculosis infection | Small molecule | Shengyang Tonglian Group Co., Ltd. |
| 2 | Fu Laimei Polyethylene Glycol Loxenatide Injection | PEG-loxenatide | 5/7/19 | GLP-1 receptor antagonist | Type 2 diabetes | Synthetic peptide analog | Hansoh Pharma |
| 3 | Camrelizumab | 5/30/19 | PD-1 inhibitor | Recurrent or refractory classical Hodgkin lymphoma | Monoclonal antibody (mAb) | Jiangsu Hengrui Medicine Co., Ltd. | |
| 4 | Xinbike | Benvitimod | 5/31/19 | Aryl hydrocarbon receptor (AhR) agonist | Psoriasis | Small molecule | Tianji Pharma |
| 5 | GV-971 | Sodium oligomannate | 11/2/19 | gut microbiota | Mild to moderate Alzheimer’s disease | Small molecule | Green Valley |
| 6 | Flumatinib mesylate | 11/26/19 | BCR-Abl inhibitor | Chronic myelogenous leukemia | Small molecule | Hansoh Pharma | |
| 7 | ZEJULA | Niraparib tosylate | 12/27/19 | PARP1/2 inhibitor | Recurrent epithelial ovarian cancer | Small molecule | Zai Lab |
| 8 | Tislelizumab | 12/27/19 | PD-1 inhibitor | Classical Hodgkin lymphoma (cHL) | Monoclonal antibody (mAb) | BeiGene | |
| 9 | Remimazolam tosylate | 12/27/19 | GABAA receptor antagonist | Sedation for routine gastroscopy | Small molecule | Jiangsu Hengrui Medicine Co. Ltd. |